Get started
BEAM THERAPEUTICS INCBEAM THERAPEUTICS INCBEAM THERAPEUTICS INC

BEAM THERAPEUTICS INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Forecast Seasonals

BEAM trade ideas

Beam $BEAM Long In the case of Beam Therapeutics ( NASDAQ:BEAM ), the weekly chart displays a promising pattern characterized by a higher low, indicating a potential bottoming process in the stock's price movement. This higher low suggests a reversal of the previous downtrend and potentially signals a shift towards bullish momentum. Moreover, technical analysis of the stock's price action identifies significant resistance lines, particularly at $39.60. If Beam Therapeutics manages to breach this resistance level, there's a projected gain of approximately 61%. Furthermore, should the stock extend its upward movement beyond this resistance point, reaching the extension level of $67.90, the potential gain could soar as high as 181%. These projections highlight the considerable upside potential for investors considering positions in Beam Therapeutics. However, it's essential to exercise caution and conduct thorough research before making investment decisions. Market conditions, company fundamentals, and external factors can all influence the stock's performance. Therefore, investors should analyze multiple indicators and seek advice from financial professionals to ensure informed and strategic investment strategies aligned with their financial goals and risk tolerance.
NASDAQ:BEAMLong
by engwicht
Cathie Wood is long BEAM, But I will be Strong Short #CathieWood Baught this stock...I analyzed it....and …...well....I would do exact the opposite...... But why? Technical Analysis Let forget eveything you know about technical analysis, and let together tell this story....logically.. At 76-71 USD AGGRESSIVE SELLERS FORCED THE PICE DOWN 29,72 USD BUYERS DEFENDED THIS Area(ZONE) as well the sellers took partial profits, and accumulated their positions ,but this time more powerfully and aggressive at 64-61USD zone THE PRICE MOVED DOWN, Institutional buyers took patial profits,(the best decision they could do OTHERWISE THEY WOULD LOSE ALL THIER PROFITS LOOK AT THE PICE OF TODAY The retail traders who followed the news and the hype baught Beam hoping that the share prce will fly to the moon,but...... At 64-61 who is waiting there? YES THE AGGRESSIVE SELLERS!!!! NOW THEY FORCED MUCH MORE ORDERS TO SEND THE PRICE To the....where we are now.... Bad for the buyers...Some buyers took profits, some took losses, and to compensate thier losses, they started to sell short the market.... At 28,80(YELLOW LINE) we are now at the weak support(low volume) The market could make a retracement to 44,94USD where the sellers and BEARS are waiting of them.....to do what? Well you know it..... Otherwise...more selles (former retail trades bulls) could decide to sell the maket from here.... WE HAVE A LONG DISTANCE TO GO DEEPER.... Targets short 13,75 8,68 3,82 1,25 . . Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (BEAM 1.11%). The gene-editing stock currently ranks as the ETF's 18th-largest holding. It's also the ninth-largest position in Wood's ARK Genomic Revolution ETF. Beam Therapeutics is a pioneer in base editing. Most types of gene editing involve double-strand breaks in DNA that can cause random unwanted insertions and deletions. Base editing is highly precise, with no double-strand breaks and no off-target genetic changes. Because of these characteristics, base editing holds tremendous promise as a method for developing therapies targeting genetic diseases and "off the shelf" cell therapies for treating cancer. So far, Beam has advanced two base-editing candidates into clinical testing. It's evaluating BEAM-101 as a treatment for two rare blood disorders: sickle cell disease and beta-thalassemia. And the company expects to begin dosing patients in a phase 1 study of experimental cancer cell therapy BEAM-201 by mid-2023. Those two programs could be joined by two others soon. Beam hopes to submit for regulatory approvals to start clinical studies of BEAM-301 as a treatment for glycogen storage disease type 1a and BEAM-302 as a treatment for severe alpha-1 antitrypsin deficiency by early 2024. The company has a long way to go. But if its base-editing programs prove to be safe and effective, Beam could be a massive winner.
CAPITALCOM:BEAMShort
by DaveBrascoFX
1
Beam me up, Scotty! BEAMWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:BEAMLong
by Rykin_Capital
$BEAM - taking small earnings dailyThis is how I have been playing this stock: Put in limit order for far less than the bottom of the spread. For example, if bid is $15.50 and ask is $20.20, I put in limit at $14.00 or less. If it fills, great, if not, no big deal It filled for the $105 strike on the 16th - $11.80 17th $11.80 19th $10.90 I set a limit sell right away from whatever the buy price + $3.00 and then adjust as the day goes on. This allowed me to book $550 last week. Small repeatable gains are working on this stock and on SNAP.
NASDAQ:BEAMLong
by katblat